Literature DB >> 7698115

Tuberculosis at the end of the twentieth century.

K A Sepkowitz1, J Raffalli.   

Abstract

Tuberculosis has once again emerged as a significant public health problem in Western countries. Much of the rise has been fueled by the growing numbers of persons infected with HIV. Co-infection with Mycobacterium tuberculosis and HIV has been shown to result in high rates of active tuberculosis, and possibly in acceleration of progression to AIDS. Primary tuberculosis occurs at high rates among dually infected persons, further emphasizing the need for effective isolation of infectious cases. Recent preliminary studies have demonstrated that the survival of persons with multidrug-resistant tuberculosis can be six months and longer, far in excess of the 4 to 12 weeks reported previously. At least seven health care workers have died of occupationally-acquired multidrug-resistant tuberculosis, making control of the spread of tuberculosis in health care settings an urgent public health priority.

Entities:  

Mesh:

Year:  1994        PMID: 7698115     DOI: 10.1007/bf02111490

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  40 in total

1.  Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users.

Authors:  N M Graham; K E Nelson; L Solomon; M Bonds; R T Rizzo; J Scavotto; J Astemborski; D Vlahov
Journal:  JAMA       Date:  1992-01-15       Impact factor: 56.272

2.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

3.  Nosocomial epidemic of active tuberculosis among HIV-infected patients.

Authors:  G Di Perri; M Cruciani; M C Danzi; R Luzzati; G De Checchi; M Malena; S Pizzighella; R Mazzi; M Solbiati; E Concia
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

4.  Malabsorption of antimycobacterial medications.

Authors:  C A Peloquin; A A MacPhee; S E Berning
Journal:  N Engl J Med       Date:  1993-10-07       Impact factor: 91.245

Review 5.  Treatment of multidrug-resistant tuberculosis.

Authors:  M D Iseman
Journal:  N Engl J Med       Date:  1993-09-09       Impact factor: 91.245

6.  High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.

Authors:  P A Selwyn; B M Sckell; P Alcabes; G H Friedland; R S Klein; E E Schoenbaum
Journal:  JAMA       Date:  1992 Jul 22-29       Impact factor: 56.272

7.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.

Authors:  J W Pape; S S Jean; J L Ho; A Hafner; W D Johnson
Journal:  Lancet       Date:  1993-07-31       Impact factor: 79.321

8.  Reinfection tuberculosis: two cases in the family of a patient with drug-resistant disease.

Authors:  P Ormerod; C Skinner
Journal:  Thorax       Date:  1980-01       Impact factor: 9.139

9.  Tuberculosis and the health care worker: a historical perspective.

Authors:  K A Sepkowitz
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

10.  Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States.

Authors:  L Slutsker; K G Castro; J W Ward; S W Dooley
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

View more
  3 in total

1.  Notification of infectious diseases by junior doctors in accident and emergency departments.

Authors:  R L Spedding; M G Jenkins; S A O'Reilly
Journal:  J Accid Emerg Med       Date:  1998-03

2.  Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece.

Authors:  P Matsiota-Bernard; G Vrioni; E Marinis
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

Review 3.  Mycobacterial taxonomy.

Authors:  T M Shinnick; R C Good
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.